Get the Stockscreener App
3.855
2.16%
-0.085
After Hours:
3.87
0.015
+0.39%
Evotec Se Adr stock is traded at $3.855, with a volume of 76,214.
It is down -2.16% in the last 24 hours and up +13.05% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$3.94
Open:
$3.92
24h Volume:
76,214
Relative Volume:
1.44
Market Cap:
$1.37B
Revenue:
$842.96M
Net Income/Loss:
$-185.63M
P/E Ratio:
-7.3303
EPS:
-0.5259
Net Cash Flow:
$-228.52M
1W Performance:
-3.87%
1M Performance:
+13.05%
6M Performance:
+25.98%
1Y Performance:
+23.56%
1-Day Range:
$3.825
$3.9465
1-Week Range:
$3.825
$4.0592
52-Week Range:
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.855 | 1.40B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - Benzinga
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Annual General Meeting - Evotec
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site By Investing.com - Investing.com South Africa
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva
SAP Quarterly Statement Q2 202522.07.25News - Ariva
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com Australia
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com Canada
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Bayer, BioNxt Solutions, Evotec – falscher Zoll Alarm bei Pharma und Biotech! Welche Aktien lohnen sich? - kapitalerhoehungen.de
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - Baystreet.ca
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):